Lower-dose treatment combo for acute myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether a lower-dose maintenance treatment can keep acute myeloid leukemia in remission after initial therapy. It uses two medicines that work together to help prevent the leukemia from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with acute myeloid leukemia (AML).
- You are age 75 or older, or age 18 to 74 with certain heart, lung, kidney, or liver problems that make standard intensive chemotherapy too risky.
- You have already responded well to initial treatment (maximum 3 cycles of standard therapy with venetoclax) and are in remission.
- You are not a candidate for intensive chemotherapy or a stem cell transplant.
- You are able to take oral medication and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, azacitidine and venetoclax, for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells left (measurable residual disease). The goal is to see if this treatment can clear those remaining cells before a stem cell transplant.
This study tests whether adding venetoclax to azacitidine after a patient reaches remission helps keep the leukemia from coming back. It is for people with acute myeloid leukemia (AML) who have completed initial treatment and are in their first remission.
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
This trial studies azacytidine (AZA) plus venetoclax as maintenance treatment to help keep acute myeloid leukemia (AML) in first remission. It may help delay or prevent AML from returning in younger adults who cannot get a stem cell transplant right away.
This trial studies whether adding venetoclax to either azacitidine or decitabine can treat acute myeloid leukemia (AML) when earlier “hypomethylating” treatment has stopped working. You might be a candidate if you’ve already tried azacitidine or decitabine for a related blood condition and it failed, and you meet the health-safety limits.
This study tests a combination of two oral and IV medicines (venetoclax and decitabine) for older adults or people who cannot receive strong chemotherapy for newly diagnosed acute myeloid leukemia (AML). The goal is to see if this gentler treatment can help control the disease with fewer side effects.
Hear when a new Acute Myeloid Leukaemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.